Lotrich and Pollock Skolnick P. 2002. Modulation of glutamate receptors: strategies for the development of novel antidepressants. Amino Acids, 23:153–9. Smith MA, Kakino S, Altemus M, et al. 1995. Stress and antidepressants differentially regulate neurotrophin 3 mRNA expression in the locus coeruleus. Proc Natl Acad Sci U S A, 92:8788–92. Song C, Lin A, Bonaccorso S, et al. 1998. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affect Disord, 49: 211–19. Srivastava SK, Nath C. 2000. The differential effects of calcium channel blockers in the behavioural despair test in mice. Pharmacol Res, 42:293–7. Stack S, Zaucha JA, Ebner FF, et al. 1998. Brain protein phosphatase 2A: developmental regulation and distinct cellular and subcellular locatization by B subunits. J Comp Neurol, 392:515–27. Steimer W, Muller B, Leucht S, et al. 2001. Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta, 308:33–41. Stergiopoulos SG, Stratakis CA. 2003. Human tumors associated with Carney complex and germline PRKAR1A mutations: a protein kinase A disease! FEBS Lett, 546:59–64. Strohle A, Holsboer F. 2003. Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry, 36:S207–14. Sugie Y, Sugie H, Fukuda T, et al. 2003. Studies on the adverse effects of fluvoxamine treatment in children with autistic disorder: correlation with genetic polymorphism in serotonin related genes. [Japanese]. No to Hattatsu, 35:233–7. Suzuki A, Kondo T, Mihara K, et al. 2001. The -141C Ins/Del poly- morphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics, 11:545–50. Svenningsson P, Tzavara ET, Witkin JM, et al. 2002. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci U S A, 99:3182–7. Tabor HK, Risch NJ, Myers RM. 2002. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev, 3:1–7. Thase ME. 1998. Depression, sleep, and antidepressants. J Clin Psychiatry, 59:55–65. Thase ME. 2003. Effectiveness of antidepressants: comparative remission rates. J Clin Psychiatry, 64:3–7. Thompson C, Peveler RC, Stephenson D, et al. 2000. Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: a randomized comparison of fluoxetine and a tricyclic antidepressant. Am J Psychiatry, 157:338–43. Torres G, Horowitz JM, Laflamme N, et al. 1998. Fluoxetine induces the transcription of genes encoding c-fos, corticotropin-releasing factor and its type 1 receptor in rat brain. Neurosci Lett, 87:463–77. Toyota T, Hattori E, Meerabux J, et al. 2002. Molecular analysis, mutation screening, and association study of adenylate cyclase type 9 gene (ADCY9) in mood disorders. Am J Med Genet, 114:84–92. Turecki G, Grof P, Cavazzoni P, et al. 1998. Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder. Mol Psychiatry, 3:534–8. Ueno S. 2003. Genetic polymorphisms of serotonin and dopamine transporters in mental disorders. J Med Investig, 50:25–31. Urwin RE, Bennetts B, Wilcken B, et al. 2002. Anorexia nervosa (restrictive subtype) is associated with a polymorphism in the novel norepinephrine transporter gene promoter polymorphic region. Mol Psychiatry, 7:652–7. van den Bree MB, Owen MJ. 2003. The future of psychiatric genetics. Ann Med, 35:122–34. van den Oord EJ, Sullivan PF. 2003. False discoveries and models for gene discovery. Trends Genet, 19:537–42. Venter JC, Adams MD, Myers EW, et al. 2001. The sequence of the human genome. Science, 291:1304–51. 34 Vicentic A, Battaglia G, Carroll RI, et al. 1999. Serotonin transporter production and degradation rates: studies with RTI-76. Brain Res, 841:1–10. Villafuerte SM, Del-Favero J, Adolfsson R, et al. 2002. Gene-based SNP genetic association study of the corticotropin-releasing hormone receptor-2 (CRHR2) in major depression. Am J Med Genet, 114: 222–6. Walsh BT, Seidman SN, Sysko R, et al. 2002. Placebo response in studies of major depression: variable, substantial, and growing. JAMA, 287:1840–7. Wang SJ, Su CF, Kuo YH. 2003. Fluoxetine depresses glutamate exocytosis in the rat cerebrocortical nerve terminals (synaptosomes) via inhibition of P/Q-type Ca2+ channels. Synapse, 48:170–7. Way KJ, Chou E, King GL. 2000. Identification of PKC-isoform specific biological actions using pharmacological approaches. Trends Pharmacol Sci, 21:181–7. Wilde MI, Markham A. 1996. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs, 52: 773–94. Wischmeyer E, Karschin A. 1996. Receptor stimulation causes slow inhibition of IRK1 inwardly rectifying K+ channels by direct protein kinase A-mediated phosphorylation. Proc Natl Acad Sci U S A, 93:5819–23. Wu WH, Huo SJ, Cheng CY, et al. 2001. Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders. Neuropsychobiology, 44:172–5. Yamada M, Yamada M, Yamazaki S, et al. 2000. Identification of a novel gene with RING-H2 finger motif induced after chronic antidepressant treatment in rat brain. Biochem Biophys Res Commun, 278:150–7. Yamamoto KK, Gonzalez GA, Biggs WHI, et al. 1988. Phosphorylation- induced binding and transcriptional efficacy of nuclear factor CREB. Nature, 334:494–8. Ye Y, Jackson K, O’Donnell JM. 2000. Effects of repeated antidepressant treatment of type 4A phosphodiesterase (PDE4A) in rat brain. J Neurochem, 74:1257–62. Yokoyama CT, Sheng Z-H, Catterall WA. 1997. Phosphorylation of the synaptic protein interaction site on N-type calcium channels inhibits interactions with SNARE proteins. J Neurosci, 17:6929–38. Yoshida K, Ito K, Sato K, et al. 2002. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsycho- pharmacol Biol Psychiatry, 26:383–6. Yoshida K, Naito S, Takahashi H, et al. 2002. Monoamine oxidase: a gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry, 26:1279–83. Yoshida K, Naito S, Takahashi H, et al. 2003. Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine. Neuropsychobiology, 48:10–3. Yoshioka M, Matsumoto M, Togashi H, et al. 1998. Central distribution and function of 5-HT6 receptor subtype in the rat brain. Life Sci, 62:1473–7. Young EA, Lopez JF, Murphy-Weinberg V, et al. 2003. Mineralocorticoid receptor function in major depression. Arch Gen Psychiatry, 60:24–8. Yu YW, Chen TJ, Hong CJ, et al. 2003. Association study of the interleukin- 1 beta (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response. Neuropsychopharmacology, 28:1182–5. Yu YW, Chen TJ, Wang YC, et al. 2003. Association analysis for neuronal nitric oxide synthase gene polymorphism with major depression and fluoxetine response. Neuropsychobiology, 47:137–40. Yu Y-Y, Tsai S-J, Chen T-J, et al. 2002. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry, 7:1115–19. Neuropsychiatric Disease and Treatment 2005:1(1)